Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMF )

15.83 +0.08 (+0.48%)
Streaming Delayed Price Updated: 11:18 AM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,478
Open 15.91
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 15.75
Today's Range 15.83 - 15.91
52wk Range 14.95 - 17.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies
 
Via Benzinga
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
The  
Via Benzinga

Performance

YTD
-3.68%
-3.68%
1 Month
+2.93%
+2.93%
3 Month
+2.13%
+2.13%
6 Month
-3.68%
-3.68%
1 Year
-11.42%
-11.42%

More News

Read More
Astellas' Menopause Drug Suffers Setback After Failed Asian Trial
Via Benzinga
Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing
Via Benzinga
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
Via Benzinga
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Via Benzinga
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
Via Benzinga
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Via Benzinga
Exposures Product Safety
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
Via Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
Via Benzinga
Exposures Product Safety
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
Via Benzinga
Exposures Product Safety
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
Via Benzinga
Exposures Product Safety
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Via Benzinga
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Astellas Takes $540M Impairment Charge Of $3B Audentes Buy­out On Gene Therapy Trial Hold
Via Benzinga
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.